Systemic lupus erythematosus sera inhibit antigen presentation by macrophages to T cells
- PMID: 3257427
- DOI: 10.1016/0090-1229(88)90192-4
Systemic lupus erythematosus sera inhibit antigen presentation by macrophages to T cells
Abstract
Several reports have demonstrated that systemic lupus erythematosus (SLE) patients have a decreased response to exogenous antigens both in vivo and in vitro. We examined the effects of SLE sera on macrophage (M phi) antigen-presenting functions. M phi from normal donors were pulsed with tetanus toxoid antigen in the presence of SLE or normal human serum (NHS), fixed in paraformaldehyde, and incubated with autologous T cells. Of 16 SLE sera tested, 11 inhibited the T-cell proliferative response (measured by [3H]thymidine uptake) compared to control NHS; mean percentage inhibition was 53 +/- 23%. This inhibition did not result from interference with antigen uptake by M phi and was found in both IgM and IgG fractions of the sera. There was a positive correlation between the amount of inhibition and the cytotoxic reactivity of the SLE sera against M phi as measured by Terasaki assay (r = 0.659, P less than 0.01). However, the presence and the amount of the inhibition did not correlate with serum immune complexes by Clq ELISA, serum anti-DR antibodies, or clinical disease activity of the SLE patients. We conclude that some SLE sera possess IgM and IgG antibodies reactive with M phi which affect M phi antigen-presenting functions, and might relate to decreased antigenic response in SLE patients.
Similar articles
-
Monocyte (macrophage)-specific antibodies in patients with systemic lupus erythematosus (SLE).J Clin Immunol. 1987 Mar;7(2):121-9. doi: 10.1007/BF00916006. J Clin Immunol. 1987. PMID: 3571434
-
T lymphocyte interaction with immunoglobulin G antibody in systemic lupus erythematosus.J Clin Invest. 1982 Apr;69(4):1026-38. doi: 10.1172/jci110506. J Clin Invest. 1982. PMID: 6978891 Free PMC article.
-
Inhibition of soluble antigen-induced T cell proliferation by warm-reactive antibodies to activated T cells in systemic lupus erythematosus.J Clin Invest. 1984 Dec;74(6):1948-60. doi: 10.1172/JCI111615. J Clin Invest. 1984. PMID: 6210306 Free PMC article.
-
The pathogenesis of systemic lupus erythematosus.Orthop Nurs. 2006 Mar-Apr;25(2):140-5; quiz 146-7. doi: 10.1097/00006416-200603000-00013. Orthop Nurs. 2006. PMID: 16572034 Review.
-
Anti-lymphocyte antibodies in systemic lupus erythematosus.Clin Rheum Dis. 1985 Dec;11(3):523-49. Clin Rheum Dis. 1985. PMID: 3907954 Review.
Cited by
-
T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity.J Clin Immunol. 1994 May;14(3):169-77. doi: 10.1007/BF01533366. J Clin Immunol. 1994. PMID: 7929693
-
A synthetic peptide from the third hypervariable region of major histocompatibility complex class II beta chain as a vaccine for treatment of experimental autoimmune encephalomyelitis.Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8005-9. doi: 10.1073/pnas.91.17.8005. Proc Natl Acad Sci U S A. 1994. PMID: 8058747 Free PMC article.
-
Cytokine-induced monocyte characteristics in SLE.J Biomed Biotechnol. 2010;2010:507475. doi: 10.1155/2010/507475. Epub 2010 Jun 24. J Biomed Biotechnol. 2010. PMID: 20625490 Free PMC article.
-
Rheumatoid arthritis and systemic lupus erythematosus: Pathophysiological mechanisms related to innate immune system.SAGE Open Med. 2019 Sep 13;7:2050312119876146. doi: 10.1177/2050312119876146. eCollection 2019. SAGE Open Med. 2019. PMID: 35154753 Free PMC article. Review.
-
Immune responses to an early lytic cytomegalovirus antigen in systemic lupus erythematosus patients: T-cell responses, cytokine secretions and antibody status.PLoS One. 2018 Mar 2;13(3):e0193244. doi: 10.1371/journal.pone.0193244. eCollection 2018. PLoS One. 2018. PMID: 29499037 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical